To investigate the prognostic significance of HSD3B1 among individuals likely to be receiving ADT, we evaluated outcomes by HSD3B1 status in a cohort of 619 men with prostate cancer who developed metastases. This evidence concerns the gene HSD3B1 and Familial prostate cancer.